Abstract 85P
Background
The purpose of this study was to compare the oncological outcomes of three preoperative chemotherapy regimens, capecitabine alone (Cap), capecitabine plus oxaliplatin (CapOx) and capecitabine plus irinotecan (CapIri), concurrent with long-course pelvic radiotherapy for patients with locally advanced rectal cancer (LARC) at a Chinese comprehensive cancer center.
Methods
LARC (T3/4 and/or LN+) cases receiving neoadjuvant treatment between Mar 2006 and Feb 2018 were reviewed. Preoperative chemoradiotherapy consisted standard fractionated pelvic radiotherapy concurrently with chemotherapy of capecitabine alone, CapOx or CapIri. Total mesorectal excision was planned 6-10 weeks after the completion of chemoradiotherapy. Tumor response, neoadjuvant treatment toxicity and surgical complications of the three cohorts were compared analyzed.
Results
A total of 1165 patients were included in the study. 445 patients received concurrent capecitabine alone, 353 received CapOx and 367 received CapIri. An abdominoperineal resection or Hartmann’s procedure was performed in 46.4%, 59.8% and 47.2% of the patients who underwent surgery in the Cap, CapOx and CapIri cohorts, respectively (P = 0.001). The complete response (CR) rate (including pathological CR and clinical CR) was 20.7%, 18.7% and 28.6% in three cohorts (P = 0.003). Multivariate analysis showed that a lower tumor location, normal baseline CEA levels and the CapIri regimen were associated with a higher CR rate. Significantly more grade 3-4 toxicity was reported in the CapIri cohort than in the other two cohorts. Patients in the CapOx cohort were more likely to report surgical complications than the other patients (Cap vs CapOx vs CapIri: 13.4% vs 21.1% vs 13.3%, P = 0.005).
Conclusions
Concurrent CapIri chemotherapy during preoperative pelvic radiotherapy significantly improved the CR rate but added toxicity compared with capecitabine alone or CapOx regimen. Long-term follow-up will determine if this short-term benefit translates into an improved survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
397P - Development of prediction model for hepatocellular carcinoma in chronic hepatitis B patients
Presenter: Teerapat Ungtrakul
Session: Poster display session
Resources:
Abstract
398P - Planning for future cancer control programs in Uganda: Projections of top five cancers’ incidence in the next decade
Presenter: Judith Asasira
Session: Poster display session
Resources:
Abstract
399P - Prevalence of colorectal cancer risk factors in apparently healthy adults in Suluhan Village, Bali
Presenter: Cindy Trisina
Session: Poster display session
Resources:
Abstract
400P - Female lung cancer: Emerging issue in Bangladesh
Presenter: Muhammad Rafiqul Islam
Session: Poster display session
Resources:
Abstract
402P - Work-related outcomes among cancer survivors in Singapore
Presenter: Chia Jie Tan
Session: Poster display session
Resources:
Abstract
407P - Focal treatments for metastatic soft tissue sarcoma (mSTS) is associated with improved overall survival
Presenter: Ching Tso Chen
Session: Poster display session
Resources:
Abstract
408P - The Asian sarcoma consortium sarcoma preceptorship program: A program evaluation study utilizing the Kirkpatrick model (Level 1 and 2)
Presenter: Fernando Gracieux Jr.
Session: Poster display session
Resources:
Abstract
409P - Integrated genomic and transcriptomic analysis revealed mutagenic patterns of dedifferentiated liposarcoma and leiomyosarcoma in Chinese patients
Presenter: Yuhong Zhou
Session: Poster display session
Resources:
Abstract
410P - Treatment patterns and outcomes of elderly patients with metastatic soft tissue sarcomas (mSTS)
Presenter: Yu-ju Kuo
Session: Poster display session
Resources:
Abstract
411P - Comparative analysis of protein profiles of prognosis-associated proteins and KIT-related proteins in gastrointestinal stromal tumour
Presenter: Yoshiyuki Suehara
Session: Poster display session
Resources:
Abstract